Adial Pharmaceuticals, Inc. (ADIL)
Largest Insider Buys in Sector
ADIL Stock Price History Chart
ADIL Stock Performance
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Insider Activity of Adial Pharmaceuticals, Inc.
Over the last 12 months, insiders at Adial Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Adial Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Adial Pharmaceuticals, Inc. have bought $70,703 and sold $474,250 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 700 shares for transaction amount of $1,918 was made by Schuyler Kevin (director) on 2023‑09‑29.
List of Insider Buy and Sell Transactions, Adial Pharmaceuticals, Inc.
| 2023-09-29 | director | 700 0.0566% | $2.74 | $1,918 | -45.86% | |||
| 2021-12-30 | director | 25,000 0.1356% | $2.69 | $67,300 | -53.00% | |||
| 2021-11-30 | Chief Executive Officer | 10,600 0.0565% | $2.75 | $29,179 | -51.80% | |||
| 2021-11-29 | Chief Executive Officer | 10,000 0.0544% | $2.59 | $25,892 | -47.27% | |||
| 2021-11-26 | director | 10,000 0.0538% | $2.85 | $28,500 | -52.28% | |||
| 2021-04-06 | Sale | Chief Medical Officer | 150,000 0.8494% | $2.50 | $375,000 | +4.38% | ||
| 2020-08-20 | Sale | Chief Medical Officer | 350,000 2.0553% | $1.21 | $423,500 | +47.02% | ||
| 2020-03-27 | director | 19,644 0.1848% | $1.36 | $26,769 | +23.91% | |||
| 2020-03-26 | Chief Executive Officer | 12,652 0.1363% | $1.47 | $18,598 | +31.54% | |||
| 2020-03-25 | Chief Executive Officer | 12,348 0.1072% | $1.13 | $13,953 | +37.90% | |||
| 2019-12-12 | Sale | Chief Medical Officer | 150,000 0.8506% | $1.00 | $150,000 | -7.45% | ||
| 2019-03-29 | Chief Medical Officer | 33,100 0.4057% | $3.47 | $114,801 | -50.44% | |||
| 2019-03-28 | Chief Medical Officer | 40,000 0.4706% | $3.15 | $125,808 | -47.53% | |||
| 2018-07-31 | Chief Executive Officer | 80,000 1.8029% | $5.00 | $400,000 | -28.75% | |||
| 2018-07-31 | director | 180,000 2.0282% | $2.50 | $450,000 | -28.75% | |||
| 2018-07-31 | director | 20,000 0.4507% | $5.00 | $100,000 | -28.75% | |||
| 2018-07-31 | director | 14,000 0.3155% | $5.00 | $70,000 | -28.75% | |||
| 2018-07-31 | director | 14,000 0.3549% | $5.63 | $78,750 | -28.75% | |||
| 2018-07-31 | 1,400 0.0316% | $5.00 | $7,000 | -28.75% |
Insider Historical Profitability
| Stilley William B. III | Chief Executive Officer | 937646 14.6375% | $1.06 | 5 | 0 | <0.0001% |
| Johnson Bankole A. | Chief Medical Officer | 548336 8.56% | $1.06 | 3 | 3 | <0.0001% |
| Gilliland Robertson H. | director | 109424 1.7082% | $1.06 | 1 | 0 | <0.0001% |
| Newman James W. Jr. | director | 50221 0.784% | $1.06 | 4 | 0 | <0.0001% |
| Goodman Tony | director | 8755 0.1367% | $1.06 | 1 | 0 | <0.0001% |